Milestones include: Mid-year presentation of additional Phase 1 data from the ongoing ENABLE trial; Regulatory alignment with the FDA on dose selection and Phase 3 trial design; Initiation of ENABLE-2, the Phase 3 clinical trial of ELVN-001, in the second half of 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics appoints new board chair amid transition
- Enliven Therapeutics Appoints Richard Fair as CEO
- Enliven announces the appointment of Fair as CEO
- Enliven Therapeutics: Strategic Advancements and Promising Clinical Progress Support Buy Rating
- Enliven Therapeutics: Promising Financial Discipline and Strategic Positioning Justify Buy Rating